Crizotinib Capsules

DRUG2 trials

Sponsors

Shouyao Holdings (Beijing) Co. LTD, Guangzhou JOYO Pharma Co., Ltd

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)Non-small Cell Lung Cancer

Phase 3

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Not yet recruitingNCT06254599

Shouyao Holdings (Beijing) Co. LTDNon-small Cell Lung Cancer

Start: 2024-05-01End: 2027-05-01Target: 255Updated: 2024-02-12

A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Not yet recruitingNCT07816380

Guangzhou JOYO Pharma Co., LtdNSCLC (Advanced Non-small Cell Lung Cancer)

Start: 2026-10-30End: 2029-12-30Target: 216Updated: 2026-09-15